Publication: Combination chemotherapy for advanced lung cancer: Survival differences between histological types and implications for prevention in Thailand
Issued Date
1996-04-22
Resource Type
ISSN
1021335X
Other identifier(s)
2-s2.0-0029985904
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Oncology Reports. Vol.3, No.3 (1996), 579-582
Suggested Citation
T. Limsila Combination chemotherapy for advanced lung cancer: Survival differences between histological types and implications for prevention in Thailand. Oncology Reports. Vol.3, No.3 (1996), 579-582. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/17544
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Combination chemotherapy for advanced lung cancer: Survival differences between histological types and implications for prevention in Thailand
Author(s)
Other Contributor(s)
Abstract
Lung cancer is now a major public health problem in Thailand. This study was undertaken to gain some preliminary data regarding the potential effectiveness in treating advanced non-small cell lung carcinoma (NSCLC) using an ifosfamide combination therapy IA(E)P. A clinical study was made of all 50 patients (Thais) with histologically proven, advanced NSCLC admitted to the University of Siriraj Hospital between 1985 and 1987 and followed up until February 1992. Survival was calculated for responders and non-responders as distinct groups, and for the different histological tumors among the responders. There were 22 cases of adenocarcinoma, 13 large cell carcinoma, and 15 squamous cell carcinoma. Twenty-seven out of 50 (54%) responded to treatment. The median survival of the response group was 17 months, compared with 5.5 months in the non-response group. The longest survival period was seen in patients with large cell carcinoma. The results suggest that moderate success might be expected in selected patients using the IA(E)P. Further work should be undertaken in developing countries using controlled clinical trials to more fully determine the efficacy of IA(E)P in treating NSCLC.